ClinConnect ClinConnect Logo
Search / Trial NCT02861482

Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage

Launched by DONGYU WANG · Aug 9, 2016

Trial Information

Current as of August 02, 2025

Completed

Keywords

Pph, Bakri Ballon

ClinConnect Summary

Data of 472 patients from 20 different hospitals had a Bakri balloon tamponade. Enrolled patients would follow the next process: assessment of blood loss intrapartum and 2 hours postpartum; laying the Bakri Balloon; assessment of blood loss, uterine contraction and complications after Bakri Balloon tamponade; further conservative surgical measures (uterine placation (B-lynch suture), arterial embolization; artery ligation; cervical cerclage) or even hysterectomy if necessary; recording the puerperium infection and involution of uterus.

Data were analyzed by SPSS 20.0 database. The results ...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women with vaginal or cesarean delivery;
  • PPH caused by: Uterine Atony, Placenta Factors, Coagulation disorders, Hematological disorders, Hepatic diseases, Obstetric DIC;
  • Not reacting well to continuous uterine massage or uterotonic agents including oxytocin (0.04IU/L ivgtt to a maximum of 60IU), Hemabate (250-500ug im) and Duratocin (100ug iv);
  • Without other conservative surgical treatment(uterine compression suture, internal arterial embolism; vascular ligation);
  • Signing the informed consents;
  • Exclusion Criteria:
  • Has undergone or will undergo conservative surgical treatment(uterine compression suture, international arterial embolism; artery ligation);
  • Impaired soft birth canal injury;
  • Untreated uterine deformity;
  • Definite indication for uterectomy.

About Dongyu Wang

Dongyu Wang is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing safe and effective therapies, Dongyu Wang collaborates with leading researchers and healthcare professionals to design and implement rigorous clinical trials. By adhering to the highest ethical standards and regulatory guidelines, the organization aims to contribute significantly to the understanding and treatment of various medical conditions, ultimately enhancing patient outcomes and public health.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Trial Officials

Zilian Wang, M.D.,PhD

Study Director

Obstetrics and Gynechology Department of the 1st affiliated hospital of Sun Yat-sen University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials